Quantinno Capital Management LP Acquires 11,762 Shares of ANI Pharmaceuticals, Inc. $ANIP

Quantinno Capital Management LP grew its stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 345.4% during the first quarter, HoldingsChannel.com reports. The firm owned 15,167 shares of the specialty pharmaceutical company’s stock after buying an additional 11,762 shares during the period. Quantinno Capital Management LP’s holdings in ANI Pharmaceuticals were worth $1,166,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in ANIP. Vanguard Group Inc. grew its stake in shares of ANI Pharmaceuticals by 2.2% during the fourth quarter. Vanguard Group Inc. now owns 1,305,068 shares of the specialty pharmaceutical company’s stock worth $103,022,000 after purchasing an additional 27,598 shares during the period. Penn Capital Management Company LLC lifted its stake in ANI Pharmaceuticals by 2,058.9% in the fourth quarter. Penn Capital Management Company LLC now owns 137,394 shares of the specialty pharmaceutical company’s stock valued at $10,858,000 after buying an additional 131,030 shares during the period. Hussman Strategic Advisors Inc. acquired a new position in ANI Pharmaceuticals in the fourth quarter valued at about $2,487,000. Artemis Investment Management LLP bought a new position in ANI Pharmaceuticals during the fourth quarter worth about $1,706,000. Finally, CenterBook Partners LP bought a new position in ANI Pharmaceuticals during the fourth quarter worth about $1,518,000. 76.05% of the stock is currently owned by institutional investors.

ANI Pharmaceuticals Stock Up 2.4%

Shares of ANI Pharmaceuticals stock opened at $76.54 on Friday. The company has a market capitalization of $1.76 billion, a P/E ratio of 16.50 and a beta of 0.44. The company has a debt-to-equity ratio of 0.99, a current ratio of 2.91 and a quick ratio of 2.41. The business has a 50-day moving average of $80.82 and a two-hundred day moving average of $79.03. ANI Pharmaceuticals, Inc. has a 1 year low of $70.15 and a 1 year high of $99.50.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings data on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share for the quarter, beating the consensus estimate of $2.04 by $0.17. ANI Pharmaceuticals had a return on equity of 27.37% and a net margin of 11.07%.The business had revenue of $266.04 million for the quarter, compared to analysts’ expectations of $260.13 million. During the same quarter in the previous year, the business posted $1.80 EPS. ANI Pharmaceuticals’s revenue for the quarter was up 25.8% on a year-over-year basis. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. As a group, equities analysts predict that ANI Pharmaceuticals, Inc. will post 8.03 EPS for the current year.

Wall Street Analyst Weigh In

ANIP has been the subject of several analyst reports. Weiss Ratings lowered ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday. Canaccord Genuity Group reduced their price objective on shares of ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating on the stock in a research note on Monday, August 10th. Zacks Research lowered shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 14th. Wall Street Zen cut shares of ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 8th. Finally, Guggenheim lowered their target price on shares of ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating for the company in a research note on Monday. Four analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, ANI Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $105.83.

Insider Activity at ANI Pharmaceuticals

In other news, VP Meredith Cook sold 500 shares of the stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $75.48, for a total transaction of $37,740.00. Following the completion of the sale, the vice president owned 74,424 shares of the company’s stock, valued at $5,617,523.52. This represents a 0.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Stephen P. Carey sold 3,313 shares of the business’s stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $86.00, for a total transaction of $284,918.00. Following the completion of the sale, the chief financial officer directly owned 177,543 shares in the company, valued at $15,268,698. This represents a 1.83% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 18,987 shares of company stock worth $1,546,405 over the last ninety days. 8.10% of the stock is owned by corporate insiders.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.